Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Puccetti, Paolo ^a   Fallarino, Francesca ^a   Italiano, Antoine ^b   Soubeyran, Isabelle ^b   MacGrogan, Gaetan ^b   Debled, Marc ^b   Velasco, Valerie ^b   Bodet, Dominique ^c   Eimer, Sandrine ^d   Veldhoen, Marc ^e   Prendergast, Georges C ^f   Platten, Michael ^g,h   Bessede, Alban ^c   Guillemin, Gilles J ^i,j  

^a UNIVERSITY OF PERUGIA   (Italy)

^b INSTITUT BERGONIÉ   (France)

^c ImmuSmol   (France)

^d Histology and Molecular Pathology of Tumors Laboratory EA 2406 University Bordeaux Segalen ^*  (France)

^e BABRAHAM INSTITUTE   (United Kingdom)

^f LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ MACQUARIE UNIVERSITY   (Australia)

^j St Vincent's Centre for Applied Medical Research   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; MONOCLONAL ANTIBODY; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE 2; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; COLORECTAL TUMOR; HUMAN; METABOLISM;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; TRYPTOPHAN;

EID: 84928248363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122046     Document Type: Article

References (37)

1. Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012; 13 (12):1129-32. doi: 10.1038/ni.2392 PMID: 23160205
2. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013; 34(3):137-43. doi: 10.1016/j.it.2012.10.001 PMID: 23103127
3. Stone TW, Darlington LG. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol. 2013; 169(6):1211-27. doi: 10.1111/bph.12230 PMID: 23647169
4. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9(10):1069-77. PMID: 12232795
5. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J Immunol. 2010.
6. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014.
7. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature medicine. 2003; 9(10):1269-74. PMID: 14502282
8. Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2014.
9. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues. Cancer immunology research. 2014.
10. Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Kruse V, Schreuer M, et al. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? Br J Dermatol. 2014; 171(5):987-95. doi: 10.1111/bjd.13100 PMID: 24814041
11. Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014; 63 (6):545-57. PMID: 24658839
12. Arpinati M, Curti A. Immunotherapy in acute myeloid leukemia. Immunotherapy. 2014; 6(1):95-106. doi: 10.2217/imt.13.152 PMID: 24341888
13. Choe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer. 2014; 14:335. doi: 10.1186/1471-2407-14-335 PMID: 24886161
14. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006; 12(4):1144-51. PMID: 16489067
15. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(7):2497-502. doi: 10.1073/pnas.1113873109 PMID: 22308364
16. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumourpromoting ligand of the human aryl hydrocarbon receptor. Nature. 2011.
17. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer research. 2007; 67(15):7082-7. PMID: 17671174
18. Rodriguez-Blanco G, Burgers PC, Dekker LJ, Vredenbregt-van den Berg MS, Ijzermans JN, Schenk- Braat EA, et al. Serum kynurenine/tryptophan ratio is not a potential marker for detecting prostate cancer. Clinical biochemistry. 2014.
19. Austin CJ, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug discovery today. 2014.
20. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007; 117(5):1147-54. PMID: 17476344
21. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013; 210 (7):1389-402. doi: 10.1084/jem.20130066 PMID: 23752227
22. Blaschitz A, Gauster M, Fuchs D, Lang I, Maschke P, Ulrich D, et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS One. 2011; 6(7):e21774. doi: 10.1371/journal.pone.0021774 PMID: 21755000
23. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297(5588):1867-70. PMID: 12228717
24. Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu XJ, et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med. 2009; 7:71. doi: 10.1186/1479-5876-7-71 PMID: 19695096
25. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res. 2011; 17(22):6985-91. doi: 10.1158/1078-0432.CCR-11-1331 PMID: 22068654
26. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006; 364(1-2):82-90. PMID: 16197934
27. Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, et al. Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One. 2014; 9(11):e112945. doi: 10.1371/journal.pone.0112945 PMID: 25415278
28. Opitz CF, Litzenburger, Sahm F, Ott M, Tritschler I, Sahm, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478:197-203. doi: 10.1038/nature10491 PMID: 21976023
29. Sperner-Unterweger B, Neurauter G, Klieber M, Kurz K, Meraner V, Zeimet A, et al. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology. 2011; 216(3):296-301. doi: 10.1016/j.imbio.2010.07.010 PMID: 20822828
30. Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis inmalignantmelanoma patients. Dermatology. 2007; 214(1):8-14. PMID: 17191041
31. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010; 67(3):361-5. doi: 10.1016/j.lungcan.2009.05.001 PMID: 19487045
32. Sakurai K, Fujisaki S, Nagashima S, Maeda T, Tomita R, Suzuki S, et al. [Indoleamine 2, 3-dioxygenase activity for breast cancer patients with recurrence 5 or more years after surgery]. Gan To Kagaku Ryoho. 2013; 40(12):1590-2. PMID: 24393858
33. Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, et al. Serum concentration of Lkynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with RCHOP. Eur J Haematol. 2010; 84(4):304-9. doi: 10.1111/j.1600-0609.2009.01393.x PMID: 19995374
34. Schroecksnadel K, Fiegl M, Prassl K, Winkler C, Denz HA, Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. Journal of cancer research and clinical oncology. 2007; 133(7):477-85. PMID: 17356858
35. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, Teo C, et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res. 2012; 72(22):5649-57. doi: 10.1158/0008-5472.CAN-12-0549 PMID: 23144293
36. Weber WP, Feder-Mengus C, Chiarugi A, Rosenthal R, Reschner A, Schumacher R, et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006; 36(2):296-304. PMID: 16385630
37. Hiramatsu R, Hara T, Akimoto H, Takikawa O, Kawabe T, Isobe K, et al. Cinnabarinic acid generated from 3-hydroxyanthranilic acid strongly induces apoptosis in thymocytes through the generation of reactive oxygen species and the induction of caspase. J Cell Biochem. 2008; 103(1):42-53. PMID: 17476692